代谢性疾病治疗新策略——靶向脂质代谢通路的药物递送

Novel Therapeutic Strategies for Metabolic Diseases-Targeting Lipid Metabolic Pathways for Drug Delivery

摘要

脂质代谢紊乱是驱动肥胖症、糖尿病、动脉粥样硬化等代谢性疾病发生发展的关键机制之一。近年来的研究表明靶向脂质代谢关键节点的药物干预策略展现出突破传统药物的潜力。首先简要总结了代谢性疾病相关的脂质代谢通路靶点，随后系统性地介绍了靶向肝脏、脂肪组织、巨噬细胞、动脉粥样硬化斑块等脂代谢活跃部位的新型靶向输送策略，旨在为探索更安全有效的代谢性疾病新疗法提供参考。

Abstract

Disorders in lipid metabolism are one of the key mechanisms driving the development of metabolic syndrome such as obesity, diabetes, and atherosclerosis. Recent studies have shown that drug targeting to critical steps in lipid metabolism demonstrated potentially enhanced therapeutic efficacy compared to conventional therapies. This review article first briefly summarizes the lipid metabolism pathway targets associated with metabolic syndrome. Subsequently, we systematically elaborate on emerging targeted delivery strategies directed toward active sites of lipid metabolism such as the liver, adipose tissue, macrophages, and atherosclerotic plaques. The article aims to provide insights developing safer and more effective new therapies against metabolic diseases.

关键词

脂质代谢通路 / 代谢性疾病 / 靶向递送 / 糖尿病 / 肥胖症 / 动脉粥样硬化

Key words

lipid metabolism pathway / metabolic disease / targeted delivery / diabetes / obesity / atherosclerosis

参考文献

[1] Madan K, Paliwal S, Sharma S,et al. Metabolic syndrome: the constellation of co—morbidities, a global threat[J].Endocr Metab Immune Disord Drug Targets, 2023, 23(12): 1491-1504.

[2] Saklayen M G. The global epidemic of the metabolic syndrome[J].Curr Hypertens Rep, 2018, 20(2): 12.

[3] Yao F, Bo Y, Zhao L,et al. Prevalence and influencing factors of metabolic syndrome among adults in China from 2015 to 2017[J].Nutrients, 2021, 13(12): 4475.

[4] Piché M E, Tchernof A, Després J P. Obesity phenotypes, diabetes, and cardiovascular diseases[J].Circ Res, 2020, 126(11): 1477-1500.

[5] Sinha S, Ahmad R, Chowdhury K,et al. Childhood obesity: a narrative review[J].Cureus, 2025, 17(4): e82233.

[6] Koliaki C, Dalamaga M, Liatis S. Update on the obesity epidemic: after the sudden rise, is the upward trajectory beginning to flatten?[J].Curr Obes Rep, 2023, 12(4): 514-527.

[7] Chew N W S, Ng C H, Tan D J H,et al. The global burden of metabolic disease: data from 2000 to 2019[J].Cell Metab, 2023, 35(3): 414-428.e3.

[8] 中华人民共和国国家卫生健康委员会医政司. 肥胖症中国诊疗指南(2024年版)[J].协和医学杂志, 2025, 16(1): 90-108.

[9] Cheng Y, Wang H, Li M. The promise of CRISPR/Cas9 technology in diabetes mellitus therapy: how gene editing is revolutionizing diabetes research and treatment[J].J Diabetes Complications, 2023, 37(8): 108524.

[10] Kumar S, Mittal A, Babu D,et al. Herbal medicines for diabetes management and its secondary complications[J].Curr Diabetes Rev, 2021, 17(4): 437-456.

[11] NCD Risk Factor Collaboration (NCD—RisC). Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population—representative studies with 141 million participants[J].Lancet, 2024, 404(10467): 2077-2093.

[12] Karakasis P, Theofilis P, Patoulias D,et al. Diabetes—driven atherosclerosis: updated mechanistic insights and novel therapeutic strategies[J].Int J Mol Sci, 2025, 26(5): 2196.

[13] Tasouli—Drakou V, Ogurek I, Shaikh T,et al. Atherosclerosis: a comprehensive review of molecular factors and mechanisms[J].Int J Mol Sci, 2025, 26(3): 1364.

[14] Porsch F, Binder C J. Autoimmune diseases and atherosclerotic cardiovascular disease[J].Nat Rev Cardiol, 2024, 21(11): 780-807.

[15] Martin S S, Aday A W, Almarzooq Z I,et al. 2024 Heart disease and stroke statistics: a report of US and global data from the American heart association[J].Circulation, 2024, 149(8): e347-e913.

[16] Petrenko V, Sinturel F, Riezman H,et al. Lipid metabolism around the body clocks[J].Prog Lipid Res, 2023, 91: 101235.

[17] Badmus O O, Hillhouse S A, Anderson C D,et al. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways[J].Clin Sci (Lond), 2022, 136(18): 1347-1366.

[18] Li M, Chi X, Wang Y,et al. Trends in insulin resistance: insights into mechanisms and therapeutic strategy[J].Signal Transduct Target Ther, 2022, 7(1): 216.

[19] Chen Z, Tian R, She Z,et al. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease[J].Free Radic Biol Med, 2020, 152: 116-141.

[20] Real J T, Ascaso J F. Lipid metabolism and classification of hyperlipaemias[J].Clin Investig Arterioscler, 2021, 33(Suppl 1): 3-9.

[21] Porter C J H, Trevaskis N L, Charman W N. Lipids and lipid—based formulations: optimizing the oral delivery of lipophilic drugs[J].Nat Rev Drug Discov, 2007, 6(3): 231-248.

[22] Omer E, Chiodi C. Fat digestion and absorption: normal physiology and pathophysiology of malabsorption, including diagnostic testing[J]. Nutr Clin Pract, 2024, 39(Suppl 1): S6-S16.

[23] Kochappan R, Cao E, Han S,et al. Targeted delivery of mycophenolic acid to the mesenteric lymph node using a triglyceride mimetic prodrug approach enhances gut—specific immunomodulation in mice[J].J Control Release, 2021, 332: 636-651.

[24] Ko C W, Qu J, Black D D,et al. Regulation of intestinal lipid metabolism: current concepts and relevance to disease[J].Nat Rev Gastroenterol Hepatol, 2020, 17(3): 169-183.

[25] Butler A E, Moin A S M, Reiner Ž,et al. High density lipoprotein—associated proteins in non—obese women with and without polycystic ovary syndrome[J].Front Endocrinol (Lausanne), 2023, 14: 1117761.

[26] Zhu Y, Xian X, Wang Z,et al. Research progress on the relationship between atherosclerosis and inflammation[J].Biomolecules, 2018, 8(3): 80.

[27] Galindo C L, Khan S, Zhang X,et al. Lipid—laden foam cells in the pathology of atherosclerosis: shedding light on new therapeutic targets[J].Expert Opin Ther Targets, 2023, 27(12): 1231-1245.

[28] Song J, Cao C, Wang Z,et al. Mechanistic insights into the regression of atherosclerotic plaques[J].Front Physiol, 2024, 15: 1473709.

[29] Fan J, Watanabe T. Atherosclerosis: known and unknown[J].Pathol Int, 2022, 72(3): 151-160.

[30] Feingold K R. Lipid and lipoprotein metabolism[J].Endocrinol Metab Clin N Am, 2022, 51(3): 437-458.

[31] Dicken W, Mehta A, Karagiannis A,et al. Statin associated muscle symptoms: an update and review[J].Prog Cardiovasc Dis, 2022, 75: 40-48.

[32] Zhang S, Hong F, Ma C,et al. Hepatic lipid metabolism disorder and atherosclerosis[J].Endocr Metab Immune Disord Drug Targets, 2022, 22(6): 590-600.

[33] Liu Y, Wang H Y, Zhou L,et al. Biodistribution, activation, and retention of proinsulin—transferrin fusion protein in the liver: mechanism of liver—targeting as an insulin prodrug[J].J Control Release, 2018, 275: 186-191.

[34] Modder M, Het Panhuis W I, Li M,et al. Liver—targeted Angptl4 silencing by antisense oligonucleotide treatment attenuates hyperlipidaemia and atherosclerosis development in APOE*3—Leiden. CETP mice[J].Cardiovasc Res, 2024, 120(17): 2179-2190.

[35] 马健, 余同林, 崔帅帅, 等. 寡核苷酸偶联物的研究进展[J].药学进展, 2024, 48(8): 565-578.

[36] Deaton A M, Dubey A, Ward L D,et al. Rare loss of function variants in the hepatokine gene INHBEprotect from abdominal obesity[J].Nat Commun, 2022, 13(1): 4319.

[37] Akbari P, Sosina O A, Bovijn J,et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes[J].Nat Commun, 2022, 13(1): 4844.

[38] Zhang X, Yu W, Li Y,et al. Drug development advances in human genetics—based targets[J].MedComm(2020), 2024, 5(2): e481.

[39] Chait A, den Hartigh L J. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease[J].Front Cardiovasc Med, 2020, 7: 22.

[40] 周伟玉, 汤其群, 刘洋. 脂肪细胞因子对代谢的调节[J].中国生物化学与分子生物学报, 2022, 38(6): 699-707.

[41] Blüher M, Mantzoros C S. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century[J].Metabolism, 2015, 64(1): 131-145.

[42] Ali S, Alam R, Ahsan H,et al. Role of adipokines (omentin and visfatin) in coronary artery disease[J].Nutr Metab Cardiovasc Dis, 2023, 33(3): 483-493.

[43] Fasshauer M, Blüher M. Adipokines in health and disease[J].Trends Pharmacol Sci, 2015, 36(7): 461-470.

[44] Zhang Y, Liu Q, Yu J,et al. Locally induced adipose tissue browning by microneedle patch for obesity treatment[J].ACS Nano, 2017, 11(9): 9223-9230.

[45] Chen K, Cheong L Y, Gao Y,et al. Adipose—targeted triiodothyronine therapy counteracts obesity—related metabolic complications and atherosclerosis with negligible side effects[J].Nat Commun, 2022, 13(1): 7838.

[46] Xue Y, Xu X, Zhang X Q,et al. Preventing diet—induced obesity in mice by adipose tissue transformation and angiogenesis using targeted nanoparticles[J].Proc Natl Acad Sci USA, 2016, 113(20): 5552-5557.

[47] Han J, Chen Y, Xu X,et al. Development of recombinant high—density lipoprotein platform with innate adipose tissue—targeting abilities for regional fat reduction[J].ACS Nano, 2024, 18(21): 13635-13651.

[48] Harvey N L, Srinivasan R S, Dillard M E,et al. Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult—onset obesity[J].Nat Genet, 2005, 37(10): 1072-1081.

[49] Cao E, Watt M J, Nowell C J,et al. Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity[J].Nat Metab, 2021, 3(9): 1175-1188.

[50] Flynn M C, Pernes G, Lee M K S,et al. Monocytes, macrophages, and metabolic disease in atherosclerosis[J].Front Pharmacol, 2019, 10: 666.

[51] Yao J, Wu D, Qiu Y. Adipose tissue macrophage in obesity—associated metabolic diseases[J].Front Immunol, 2022, 13: 977485.

[52] 杭越. 应用于动脉粥样硬化治疗的巨噬细胞膜仿生纳米递药系统研究[D].南京: 东南大学, 2022.

[53] Gao C, Huang Q, Liu C,et al. Treatment of atherosclerosis by macrophage—biomimetic nanoparticles viatargeted pharmacotherapy and sequestration of proinflammatory cytokines[J].Nat Commun, 2020, 11(1): 2622.

[54] Wang Y, Tang B, Long L,et al. Improvement of obesity—associated disorders by a small—molecule drug targeting mitochondria of adipose tissue macrophages[J].Nat Commun, 2021, 12(1): 102.

[55] Zhu Y, Xu Y, Han D,et al. Scavenger receptor—AI targeted theranostic nanoparticles for regression of atherosclerotic plaques viaABCA1 modulation[J].Nanomedicine, 2023, 50: 102672.

[56] Chen L, Zhou Z, Hu C,et al. Platelet membrane—coated nanocarriers targeting plaques to deliver anti—CD47 antibody for atherosclerotic therapy[J].Research (Wash D C), 2022, 2022: 9845459.

[57] He Z S, Chen W, Hu K,et al. Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment[J].Nat Nanotechnol, 2024, 19(9): 1386-1398.

基金资助

江苏省药物分子设计与成药性优化重点实验室项目(DDORC202202)